The pharmaceutical Almirall has signed an agreement with Dermira to acquire the option to license rights in Europe to develop and market the lebrikizumab antibody, used for the treatment of atopic dermatitis, for a price of 30 million dollars. Lebrikizumab is an anti-IL-13 monoclonal antibody that is currently under development in phase 2b and it is expected that its potential will begin to be known at the beginning of April 2019.
In a statement, Almirall said Tuesday that this first payment of 30 million dollars could be completed with another 50 million if the pharmaceutical company opts to exercise its option to obtain the license, based on the results of the study. In addition, Dermira would receive additional payments for milestones in development, approval and sales, as well as double-digit royalties.
If Almirall finally exercises its option, it will also be obliged to make additional payments to Dermira by reaching certain milestones, including $ 30 million at the start of certain Phase 3 clinical trials, and up to $ 85 million upon reaching the regulatory milestones and the first sale. commercial of lebrikizumab in Europe.
"At Almirall, we continue to deepen our commitment to dermatology." Atopic dermatitis is a condition that affects millions of people living in Europe, and we are pleased to support the development and commercialization of lebrikizumab, a differentiated treatment that we believe could be the best therapy against the disease for these patients, "said Peter Guenter, CEO of Almirall.